# The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis

> **NCT05772520** · PHASE2 · COMPLETED · sponsor: **Hangzhou Highlightll Pharmaceutical Co., Ltd** · enrollment: 82 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** TLL018 tablets

## Key facts

- **NCT ID:** NCT05772520
- **Lead sponsor:** Hangzhou Highlightll Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-19
- **Primary completion:** 2024-12-01
- **Final completion:** 2024-12-23
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2024-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05772520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05772520, "The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT05772520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*